Immunome/$IMNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunome
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Ticker
$IMNM
Sector
Primary listing
Employees
206
Headquarters
Website
Immunome Metrics
BasicAdvanced
$2.1bn
-
-$2.34
2.12
-
Price and volume
Market cap
$2.1bn
Beta
2.12
52-week high
$27.65
52-week low
$7.96
Average daily volume
1.2m
Financial strength
Current ratio
21.681
Quick ratio
21.257
Long term debt to equity
0.627
Total debt to equity
0.627
Profitability
EBITDA (TTM)
-226.35
Gross margin (TTM)
-4,552.43%
Net profit margin (TTM)
-5,593.85%
Operating margin (TTM)
-5,698.83%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-29.72%
Return on equity (TTM)
-50.14%
Valuation
Price to revenue (TTM)
438.008
Price to book
3.53
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
-8.197
Free cash flow yield (TTM)
-12.20%
Free cash flow per share (TTM)
-2.24
Growth
Revenue change (TTM)
-63.29%
Earnings per share change (TTM)
-25.13%
3-year revenue growth (CAGR)
19.31%
3-year earnings per share growth (CAGR)
-1.89%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Immunome News
AllArticlesVideos
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Business Wire·1 day ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs